HALOHealthcare · BiotechnologyThe 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $105 — -5.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 6 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $92 → $93 |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $115 |
| 7 Aug 2026 | Leerink Partners | Upgrade | Outperform | $83 → $110 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $96 → $105 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $95 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $96 → $93 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | Benchmark | Maintains | Buy | — |
| 19 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HALO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Halozyme Therapeutics, Inc. returned +67.8% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 18% of US stocks
Cheaper than 2% of US stocks
Cheaper than 26% of US stocks
Higher than 85% of US stocks
Higher than 71% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 86% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Halozyme Therapeutics, Inc. has a market value of $12.5B and an enterprise value of $14.4B.
Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.
Net income over the same four quarters: $413.6M, a 24.9% net margin.
Diluted earnings per share, trailing twelve months: $3.35.
Free cash flow in the twelve months to 30 June 2026: $518.5M.
Trailing P/E: 32.1×; forward P/E: 10.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Halozyme expanded its ENHANZE collaboration and licensing agreement with argenx to cover eight targets. The expanded pact creates the opportunity for new milestones and royalties.
Why it matters — HALO watchers may follow the agreement for potential milestone and royalty revenue as the collaboration expands.
Halozyme said a Dutch patent court ruled in its favor against Merck, ordering Merck to halt the manufacture and sale of injectable Keytruda in eight European markets.
Why it matters — The court order is relevant to HALO watchers because it concerns Halozyme's patent dispute with Merck over injectable Keytruda in Europe.
A Dutch patent court in The Hague found Merck infringed Halozyme’s EP 2,797,622 patent and ordered MSD BV to stop specified manufacturing, marketing, distribution, and related activities involving Keytruda SC in eight European markets.
Why it matters — The ruling restricts Keytruda SC-related activities in those markets and concerns Halozyme’s patent rights.
Halozyme expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. The expansion increases argenx’s exclusive access to ENHANZE® from six targets to eight.
Why it matters — The expanded agreement adds two targets to Halozyme’s ENHANZE® collaboration with argenx, building on the development of VYVGART Hytrulo.
Halozyme Therapeutics announced the appointment of James "Jim" Daly to its Board of Directors. The announcement was made on September 30, 2026, via press release from the company's headquarters in San Diego.
Why it matters — A new board member could bring fresh perspective and experience to the company's governance, which HALO watchers may consider when assessing the company's strategic direction.
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $105, with estimates ranging from $70 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Halozyme Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies -5.2% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $115 over the next 12 months.
Halozyme Therapeutics, Inc. returned +67.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines.
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX". Halozyme expanded its ENHANZE collaboration and licensing agreement with argenx to cover eight targets. The expanded pact creates the opportunity for new milestones and royalties.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com
